Informations générales (source: ClinicalTrials.gov)

NCT06726720 En recrutement IDF
A Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating AstraZeneca (or Alliance Developed) Drugs
Observational
  • Carcinome pulmonaire non à petites cellules
  • Tumeurs du poumon
AstraZeneca (Voir sur ClinicalTrials)
décembre 2024
juin 2032
02 avril 2026
This is an ambispective, observational, multicenter and multicohort study, targeting patients with NSCLC initiating approved drugs developed by AZ or as part of an AZ alliance, in the participating countries, as monotherapy or in combination at any stage of disease. Three cohorts are designed, based on the stage of NSCLC (resectable, unresectable and metastatic). The multicohort study is modular in design. Specific modules will be set up separately to assess each new indication of drugs developed by AZ or as part of an AZ alliance once European marketing authorization (MA) has been granted and made available in the participating countries. Patients will be enrolled in the study if they have received (retrospective), receive (retrospective and prospective) or will receive (prospective) approved drugs developed by AZ or as part of an AZ alliance according to the eligibility criteria. Treatment plan and decision are made independently by each treating physician prior to inclusion in this study.

Etablissements

Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données
HOPITAL FOCH Jaafar BENNOUNA En recrutement IDF 11/05/2026 07:26:36  Contacter
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Research Site - 01012 - Bourg-en-Bresse - France Contact (sur clinicalTrials)
Research Site - 06000 - Nice - France Contact (sur clinicalTrials)
Research Site - 10000 - Troyes - France Contact (sur clinicalTrials)
Research Site - 11010 - Carcassonne - France Contact (sur clinicalTrials)
Research Site - 13003 - Marseille - France Contact (sur clinicalTrials)
Research Site - 13100 - Aix-en-Provence - France Contact (sur clinicalTrials)
Research Site - 13285 - Marseille - France Contact (sur clinicalTrials)
Research Site - 13915 - Marseille - France Contact (sur clinicalTrials)
Research Site - 14052 - Caen - France Contact (sur clinicalTrials)
Research Site - 15000 - Aurillac - France Contact (sur clinicalTrials)
Research Site - 22000 - Saint-Brieuc - France Contact (sur clinicalTrials)
Research Site - 22100 - Dinan - France Contact (sur clinicalTrials)
Research Site - 28102 - Dreux - France Contact (sur clinicalTrials)
Research Site - 28630 - Le Coudray - France Contact (sur clinicalTrials)
Research Site - 30029 - N MES - France Contact (sur clinicalTrials)
Research Site - 31076 - Toulouse - France Contact (sur clinicalTrials)
Research Site - 33000 - Bordeaux - France Contact (sur clinicalTrials)
Research Site - 34500 - Béziers - France Contact (sur clinicalTrials)
Research Site - 36019 - Châteauroux - France Contact (sur clinicalTrials)
Research Site - 41016 - Blois - France Contact (sur clinicalTrials)
Research Site - 42100 - Saint-Etienne - France Contact (sur clinicalTrials)
Research Site - 42271 - Saint-Priest-en-Jarez - France Contact (sur clinicalTrials)
Research Site - 44200 - Nantes - France Contact (sur clinicalTrials)
Research Site - 44800 - Saint-Herblain - France Contact (sur clinicalTrials)
Research Site - 49933 - Angers - France Contact (sur clinicalTrials)
Research Site - 51430 - Bezannes - France Contact (sur clinicalTrials)
Research Site - 51726 - Reims - France Contact (sur clinicalTrials)
Research Site - 54100 - Nancy - France Contact (sur clinicalTrials)
Research Site - 54519 - Vandœuvre-lès-Nancy - France Contact (sur clinicalTrials)
Research Site - 56017 - Vannes - France Contact (sur clinicalTrials)
Research Site - 57000 - Metz - France Contact (sur clinicalTrials)
Research Site - 57070 - Metz - France Contact (sur clinicalTrials)
Research Site - 59300 - Valenciennes - France Contact (sur clinicalTrials)
Research Site - 66000 - Perpignan - France Contact (sur clinicalTrials)
Research Site - 67000 - Strasbourg - France Contact (sur clinicalTrials)
Research Site - 68100 - Mulhouse - France Contact (sur clinicalTrials)
Research Site - 69100 - Villeurbanne - France Contact (sur clinicalTrials)
Research Site - 69437 - Lyon - France Contact (sur clinicalTrials)
Research Site - 69655 - Villefranche-sur-Saône - France Contact (sur clinicalTrials)
Research Site - 71321 - Chalon Sur Sa Ne - France Contact (sur clinicalTrials)
Research Site - 73000 - Chambéry - France Contact (sur clinicalTrials)
Research Site - 74370 - Epagny METZ Tessy - France Contact (sur clinicalTrials)
Research Site - 76000 - Rouen - France Contact (sur clinicalTrials)
Research Site - 76202 - Dieppe - France Contact (sur clinicalTrials)
Research Site - 77100 - Meaux - France Contact (sur clinicalTrials)
Research Site - 84918 - Avignon - France Contact (sur clinicalTrials)
Research Site - 87000 - Limoges - France Contact (sur clinicalTrials)
Research Site - 89000 - Auxerre - France Contact (sur clinicalTrials)
Research Site - 92151 - Suresnes - France Contact (sur clinicalTrials)
Research Site - 92200 - Neuilly-sur-Seine - France Contact (sur clinicalTrials)
Research Site - 94000 - Créteil - France Contact (sur clinicalTrials)
Research Site - 97200 - Fort de France Cedex - France Contact (sur clinicalTrials)

Critères

Tous


- Adult patients (≥ 18 years old)

- Patients with histologically or cytologically proven NSCLC

- Patients initiated with approved drugs developed by AZ or as part of an AZ alliance
at the time of the enrollment or within the previous three weeks.

- Informed patients who consent to participate in the study as per local regulations.

Exclusion Criteria:


- Patients participating in an interventional clinical trial for NSCLC*

* with the exception on low-interventional studies (RIPH2) where the intervention
does not involve the NSCLC treatment

- Patients already enrolled in another module of the cohort in UMBREALUNG

- Patients under safeguard of justice, curatorship or guardianship